Hyloris Pharmaceuticals S.A.
HYL.BR · BRU
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €189,932 | €357,005 | €315,508 | €446,905 |
| - Cash | €23,594 | €30,406 | €43,457 | €50,012 |
| + Debt | €1,815 | €1,751 | €885 | €12,289 |
| Enterprise Value | €168,153 | €328,350 | €272,936 | €409,182 |
| Revenue | €10,042 | €2,087 | €2,951 | €3,096 |
| % Growth | 381.2% | -29.3% | -4.7% | – |
| Gross Profit | €9,815 | €1,994 | €2,857 | €2,989 |
| % Margin | 97.7% | 95.5% | 96.8% | 96.5% |
| EBITDA | -€4,848 | -€14,980 | -€11,433 | -€10,781 |
| % Margin | -48.3% | -717.8% | -387.4% | -348.2% |
| Net Income | -€6,342 | -€15,380 | -€11,906 | -€11,579 |
| % Margin | -63.2% | -736.9% | -403.5% | -374% |
| EPS Diluted | -0.22 | -0.55 | -0.44 | -0.45 |
| % Growth | 60% | -25% | 2.2% | – |
| Operating Cash Flow | -€6,703 | -€12,808 | -€13,154 | -€11,250 |
| Capital Expenditures | -€29 | -€298 | -€739 | -€1,061 |
| Free Cash Flow | -€6,732 | -€13,106 | -€13,893 | -€12,311 |